The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDAŃSK, Poland, ...

New research points to a possible link between diet and cancer development.

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

SINGAPORE — A study of how certain white blood cells — called T cells — respond to the dengue virus has yielded promising findings that may pave the way for a possible vaccine against the disease.

The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDANSK, Poland ...

Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...